(Stroke. 1996;27:1211-1214.)
© 1996 American Heart Association, Inc.
Articles |
Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy
the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy).
Correspondence to M. Dam, Department of Neurology and Psychiatry, University of Padua, via Giustiniani 5, 35128 Padua, Italy. E-mail Clneurol@ipdunidx.unipd.it.
Background and Purpose In animals, drugs that increase brain amine concentrations influence the rate and degree of recovery from cortical lesions. It is therefore conceivable that antidepressants may influence outcome after ischemic brain injury in humans. We evaluated the effects of the norepinephrine reuptake blocker maprotiline and the serotonin reuptake blocker fluoxetine on the motor/functional capacities of poststroke patients undergoing physical therapy.
Methods Fifty-two severely disabled hemiplegic subjects were randomly assigned to three treatment groups; during 3 months of physical therapy, patients were treated with placebo, maprotiline (150 mg/d), or fluoxetine (20 mg/d). Before and at the end of the observation period, we assessed activities of daily living by the Barthel Index, degree of neurological deficit by a neurological scale for hemiplegic subjects, and depressive symptomatology by the Hamilton Depression Rating Scale.
Results The diverse treatments ameliorated walking and activities of daily living capacities to different extents. The greatest improvements were observed in the fluoxetine-treated group and the lowest in the maprotiline-treated group. Furthermore, fluoxetine yielded a significantly larger number of patients with good recovery compared with maprotiline or placebo. These effects of the drugs were not related to their efficacy in treating depressive symptoms.
Conclusions Fluoxetine may facilitate or, alternatively, maprotiline may hinder recovery in poststroke patients undergoing rehabilitation. The effects of fluoxetine as an adjunct to physical therapy warrant further investigation, since treatment with fluoxetine may result in a better functional outcome from stroke than physical therapy alone.
Key Words: antidepressive agents • fluoxetine • maprotiline • rehabilitation • stroke outcome
This article has been cited by other articles:
 |
|
 |
|
  S. Zittel, C. Weiller, and J. Liepert Citalopram Improves Dexterity in Chronic Stroke Patients Neurorehabil Neural Repair, June 1, 2008; 22(3): 311 - 314. [Abstract] [PDF]
|
|
|
|
 |
|
 S. C. Cramer, W. J. Koroshetz, and S. P. Finklestein The Case for Modality-Specific Outcome Measures in Clinical Trials of Stroke Recovery-Promoting Agents Stroke, April 1, 2007; 38(4): 1393 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, J. J Guo, S. Zhan, and N. C Patel Treatment Effects of Antidepressants in Patients with Post-Stroke Depression: A Meta-Analysis Ann. Pharmacother., December 1, 2006; 40(12): 2115 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Ziemann, F. Meintzschel, A. Korchounov, and T. V. Ilic Pharmacological Modulation of Plasticity in the Human Motor Cortex Neurorehabil Neural Repair, June 1, 2006; 20(2): 243 - 251. [Abstract] [PDF]
|
|
|
|
|
|
B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duncan, R. Zorowitz, B. Bates, J. Y. Choi, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, and D. Reker Management of Adult Stroke Rehabilitation Care: A Clinical Practice Guideline Stroke, September 1, 2005; 36(9): e100 - e143. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hackett, C. S. Anderson, and A. O. House Management of Depression After Stroke: A Systematic Review of Pharmacological Therapies Stroke, May 1, 2005; 36(5): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J C Davies, P. R Jackson, J. Potokar, and D. J Nutt Treatment of anxiety and depressive disorders in patients with cardiovascular disease BMJ, April 17, 2004; 328(7445): 939 - 943. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Charney, C. F. Reynolds III, L. Lewis, B. D. Lebowitz, T. Sunderland, G. S. Alexopoulos, D. G. Blazer, I. R. Katz, B. S. Meyers, P. A. Arean, et al. Depression and Bipolar Support Alliance Consensus Statement on the Unmet Needs in Diagnosis and Treatment of Mood Disorders in Late Life Arch Gen Psychiatry, July 1, 2003; 60(7): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rasmussen, M. Lunde, D. L. Poulsen, K. Sorensen, S. Qvitzau, and P. Bech A Double-Blind, Placebo-Controlled Study of Sertraline in the Prevention of Depression in Stroke Patients Psychosomatics, June 1, 2003; 44(3): 216 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Calautti and J.-C. Baron Functional Neuroimaging Studies of Motor Recovery After Stroke in Adults: A Review Stroke, June 1, 2003; 34(6): 1553 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Turner-Stokes and N. Hassan Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives Clinical Rehabilitation, March 1, 2002; 16(3): 248 - 260. [Abstract] [PDF]
|
|
|
|
 |
|
 S. VALE Medical urology. Postgrad. Med. J., September 1, 2000; 76(899): 596 - 597. [Full Text]
|
|
|
|
|
|
L. Wiart, H. Petit, P. A. Joseph, J. M. Mazaux, and M. Barat Fluoxetine in Early Poststroke Depression : A Double-Blind Placebo-Controlled Study Stroke, August 1, 2000; 31(8): 1829 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duncan, H. S. Jorgensen, and D. T. Wade Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice Stroke, June 1, 2000; 31(6): 1429 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Zorowitz Neurorehabilitation of the Stroke Survivor Neurorehabil Neural Repair, June 1, 1999; 13(2): 83 - 92. [PDF]
|
|
|
|
|
|
M. M. Bednar and C. E. Gross Antiplatelet Therapy in Acute Cerebral Ischemia Stroke, April 1, 1999; 30(4): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dahmen, J. Marx, H. C. Hopf, B. Tettenborn, and R. Roder Therapy of Early Poststroke Depression With Venlafaxine: Safety, Tolerability, and Efficacy as Determined in an Open, Uncontrolled Clinical Trial Stroke, March 1, 1999; 30(3): 691 - 692. [Full Text] [PDF]
|
|
|
|
|
|
R. Ramasubbu, A. Flint, G. Brown, G. Awad, and S. Kennedy Diminished Serotonin-Mediated Prolactin Responses in Nondepressed Stroke Patients Compared With Healthy Normal Subjects Stroke, July 1, 1998; 29(7): 1293 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Herrmann, S.E. Black, J. Lawrence, C. Szekely, and J.P. Szalai The Sunnybrook Stroke Study : A Prospective Study of Depressive Symptoms and Functional Outcome Stroke, March 1, 1998; 29(3): 618 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Miyai and M. J. Reding Effects of Antidepressants on Functional Recovery Following Stroke: A Double-Blind Study Neurorehabil Neural Repair, January 1, 1998; 12(1): 5 - 13. [Abstract] [PDF]
|
|